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est anti-cancer drugs, interferons, and recombinant DNA
agents, etc.); the methodology for performing these stud-
ies generally requires separate estimations of the mean
lifetime survival (MLS) for the innovative treatment and
for the reference treatment.
METHODS: Mean survival gain (MSG), which is ex-
pressed in life-years (or months) gained per patient using
the new treatment as opposed to the other, is the differ-
ence between the two values of MLS observed with the
two treatments and is generally calculated according to
the methods of Markov or Gompertz. We have con-
ducted a literature search of studies reporting these esti-
mates of MSG.
RESULTS: The table below illustrates some values of
MSG for a series of different therapeutic problems:
CONCLUSION: The MSG can be proposed as a simple
and objective index to quantify the degree of innovation
of new treatments.
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Health-related quality of life (HRQoL) measures are in-
creasingly important for evaluating health programs and
health outcomes. Understanding the clinical and socioeco-
nomic determinants of HRQoL is a related, but relatively
little studied, topic. It is often difficult to study such rela-
tionships for large samples of individuals, because large
health survey data sets rarely include HRQoL measures.
OBJECTIVE: This paper attempts to address this prob-
lem by demonstrating the feasibility and utility of linking
algorithms for well-known quality of life indicators to
large, nationally representative databases. This process
allows the advantages of HRQoL indicators to be com-
bined with the benefits of large, nationally representative
data sets.
METHODS: We illustrate this approach using the Na-
tional Medical Expenditure Survey (NMES) and the Euro-
Qol and drawing on a previous match of the Health Util-
ity Index (HUI) with NMES. Although the NMES data
allow a good match to the EuroQol and the HUI, the
matches are not perfect. Thus we conduct sensitivity
analysis using several related specifications of each indi-
cator. We analyze the correlation of the several specifica-
tions within each set of specifications of HUI and Euro-
Qol and across the two, HUI and EuroQol.
RESULTS: By examining the within domain correlations
and the between correlations, we find that the alternate
specifications within domain are very similar and that the
two HRQoL indicators are similar in many but not all
ways. We analyze construct validity by examining the
performance of the HUI and EuroQols in empirical situa-
tions in which we have knowledge about the relation-
ships (e.g., health decreases with aging). 
CONCLUSIONS: The results suggest good construct va-
lidity.
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Cost-utility analyses conducted in phase III clinical trials
have typically obtained preference values for health out-
comes from one of two sources: direct interviews of trial
subjects, or a generic health status index to assign prefer-
ence weights to subjects. But the interview approach has
been criticized because of concerns about administrative
feasibility and generalizability. The generic instrument
approach usually requires the investigator to make sub-
jective judgments in mapping a subject’s clinical profile
into a (pre-computed) preference weight.
OBJECTIVE: This paper introduces a third approach and
tests its viability in a trial comparing rheumatoid arthritis
therapies.
METHODS: Specifically, we: (1) identified a “surrogate
sample” of arthritis patients (N  123) who were clinically
comparable to trial subjects; (2) elicited their preference
(utility) ratings for their own current (arthritis-affected)
state of health; (3) estimated a multivariable regression
model relating the surrogate-sample utility scores to these
patients’ functional status, clinical symptoms, and demo-
graphics; (4) used these regressions to assign utility scores
to trial subjects at each scheduled encounter; and (5) com-
puted encounter-specific mean utility scores for each treat-
ment group.
Disease condition Innovative treatment Standard treatment
Mean survival gain
(mo per pt)
Acute myocardial infarction TPA Streptokinase 1.08**
High-risk resected cutaneous melanoma Interferon No adjuvant therapy 15.9**
Node-positive breast cancer Adjuvant CMF No adjuvant chemotherapy 12.7**
Advanced ovarian cancer Paclitaxel 
 cisplatin Standard chemotherapy 5.2**
Hepatitis C Interferon (6 mo) No specific treatment 3.0**
Advanced pancreatic cancer Gemcitabine Fluorouracil 3.0*
*with 3% annual discounting; **with 5% annual discounting.
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RESULTS AND CONCLUSION: The conclusions are: (1)
it is feasible to use a surrogate sample to estimate regres-
sion models that satisfactorily relate patient utility to
readily collectible predictor variables; (2) these models can
be applied to assign plausible utility scores to subjects in a
phase III clinical trial; (3) the resulting ranking of therapies
is in accord with clinical findings from the present trial;
and (4) this strategy may be especially attractive for cost-
utility analyses that pool data from multiple trials.
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The level of uncertainty regarding the outcome of a phar-
macoeconomic study cannot be covered completely by
the statistical methods routinely employed to handle un-
certainty in clinical research. Sensitivity analysis is the
most common methodology to deal with the extra uncer-
tainty associated with pharmacoeconomics, which has
also been incorporated in recent guidelines on health care
evaluation. However, the execution of a sensitivity analy-
sis and the interpretation of the results is not yet stan-
dardized, which may lead to subjectivity and conse-
quently weakening of the value of economic evaluations. 
OBJECTIVE: The concept of point-sensitivity was used
to develop a method which allows a more objective judg-
ment of the robustness of a model by avoiding the subjec-
tiveness in most current economic studies.
RESULTS: However, a limitation of this method is that
the sensitivity measurement is based on a uniform distri-
bution of the variables, which may actually have different
distributions. A second limitation is that the overall sensi-
tivity measure is based on a subjectively chosen range, ex-
cluding the impact of values outside the range on overall
sensitivity.
CONCLUSION: The present study presents a refinement
of the method by the incorporation of probability distri-
butions, which allow a more accurate assessment of the
level of uncertainty in the model. In addition, a bootstrap
method is used to create probability distribution for fixed
input variables based on a limited number of data points.
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OBJECTIVES: Our objective is to diminish the cost of a
group of highly prescribed drugs in the Comunidad Va-
lenciana (Spain) through the promotion of prescribing
them by drug (generic) name (not registered [brand]
names), and the corresponding dispensation at phar-
macies of a selected group of registered drugs with the
same composition and size and lower price (i.e., reference
drugs). 
METHODS: The drugs representing about 50% of the
drug prescription costs for the Health Service in June
1995 were selected through analysis of pharmacy bills.
The most prescribed sizes for each drug were studied in
order to select those with minimum prices as reference
drugs. An agreement was concluded with pharmacies to
dispense these trade names when the prescription was
made by drug name. Physicians were informed in order to
promote prescription by drug name.
RESULTS: Thirty-four drugs were responsible for 45% of
the drug prescription bill of the Health Service in the
Comunidad Valenciana in June 1995. The first 10 of them
were Omeprazole, Nimodipine, Ciprofloxacin, Enalapril,
Calcitonin, Diltiazem, Fluoxetine and Nifedipine. Glob-
ally, prescriptions by drug name have increased from 0.2%
to 0.34% in 5 months. Prescription of registered names of
minimum price has increased markedly for nearly each
drug. For example, with Amoxicyllin, prescription of refer-
ence drugs in 1995 was 14.62% of the total of Amoxicyl-
lin prescriptions compared with 35.92% in 1996; for Di-
clofenac, prescriptions of reference drugs represented
15.02% of the total of Diclofenac prescriptions in 1995
compared with 31.85% in 1996. 
CONCLUSIONS: The minimum increase in dispensation of
prescription by drug names is influenced by the fact that in
Spain no generic drugs are available, and so there is a strong
tradition of prescribing by registered drug names. The agree-
ment with pharmacies represents the dispensation of a
group of selected trade names of minimum prices (reference
drugs); physicians have preferred prescribing directly the
names included in this group. The effect of diminishing
costs has been obtained with this intervention, but not by
the increase in prescriptions by drug name, as the impact
of this measure in prescribing habits has been slight.
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Meta-analysis has become an increasingly accepted re-
search tool for producing overviews of the results of clin-
ical studies. Recently, there has been a rapid increase in
the number of economic evaluations performed, and there
is both the need and the potential to produce overviews
for policy makers.
OBJECTIVE: The purpose of this research was to investi-
gate whether standard meta-analytical approaches (as ap-
plied to clinical data) could be applied to economic evalua-
tions. As a case study, an economic meta-analysis (EMA)
was conducted of cost-effectiveness analyses involving
